Aerovate Therapeutics, Inc. (AVTE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
930 Winter Street
Waltham, MA 02116
United States of America (the)
Phone
617 443 2400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 30, 2021
| Name | Title | Pay | Year Born |
| Timothy Noyes | Chief Executive Officer & Director | 936,899 | 1962 |
| Ralph W. Niven M.R Pharm.S | Chief Scientific Officer | 372,333 | 1960 |
| Benjamin T. Dake | Founder, President, Chief Operating Officer & Secretary | 435,500 | 1976 |
| Hunter Gillies | Chief Medical Officer | 512,742 | 1966 |
| George A. Eldridge | Chief Financial Officer & Treasurer | 658,600 | 1963 |
| Sanjeev Khindri | Executive Vice President of Clinical Development | 0 | N/A |
| Susan Fischer | Executive Vice President of Development Operations | 0 | N/A |
| Cheryl Lassen | Senior Vice President of Clinical Development | 0 | N/A |
| Stephen Yu | Senior Vice President of Quality | 0 | N/A |
| Donna Dea | Head of Regulatory Affairs | 0 | N/A |
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.